Introduction
prostate cancer
METASTATIC PROSTATE CANCER
Androgen deprivation therapy is standard of care for advanced or metastatic prostate cancer [The insulin-like growth factor (IGF) axis plays an important role in prostate cancer progression. Castration leads to increased signalling via the type I IGF tyrosine kinase receptor (IGF-1R), activating the PI3K/AKT/mTOR pathway [Xentuzumab is a humanised monoclonal antibody that binds to and neutralises the IGF-1 and IGF-2 ligands [This Phase Ib/II trial evaluated xentuzumab plus enzalutamide in patients with metastatic CRPC (mCRPC). In patients who had progressed on docetaxel-based chemotherapy and abiraterone, a Phase Ib dose escalation part was conducted to determine the maximum tolerated dose (MTD), and a randomised Phase II part assessed the combination versus enzalutamide alone. A Phase Ib expansion cohort evaluated the addition of xentuzumab to enzalutamide in docetaxel/abiraterone naïve patients experiencing prostate-specific antigen (PSA) progression on enzalutamide.